Appropriateness of Antihyperlipidemic Prescribing at RSU Imelda Pekerja Indonesia: A Retrospective Medical Record Study / Ketepatan Peresepan Obat Antihiperlipidemia di RSU Imelda Pekerja Indonesia: Studi Retrospektif Rekam Medis

Background: Prescribing audits provide a basis for evaluating the appropriateness of antihyperlipidemic treatment in clinical practice. Objective: To describe prescribing patterns and assess documentation-based appropriateness at RSU Imelda Pekerja Indonesia, Medan. Methods: This descriptive study retrospectively reviewed medical records from March 2025 to February 2026. Data were collected in June 2026, and 51 patients were selected by purposive sampling. Patient, indication, drug, dose, and route appropriateness were assessed with reference to the 2021 Indonesian Society of Endocrinology (PERKENI) guidance. Data were summarized using frequencies, percentages, and exact 95% confidence intervals (CIs). Results: Women accounted for 32 patients (62.75%); the largest age group was 56–65 years (16; 31.37%). Simvastatin 20 mg, atorvastatin 20 mg, and fenofibrate 300 mg monotherapy were recorded in 26 (50.98%), 19 (37.25%), and four (7.84%) patients, respectively. Two patients (3.92%) received simvastatin 20 mg plus fenofibrate 100 mg. Statin monotherapy accounted for 88.24% of patients (95% CI, 76.13–95.56%). All 51 records were classified as appropriate for each criterion (100%; 95% CI, 93.02–100.00%). Conclusion: Statin monotherapy predominated, and no documented inappropriateness was identified within the five assessed criteria. These findings describe prescribing classifications, not comprehensive treatment safety or lipid-target attainment. Further evaluation should link prescribing decisions to individual cardiovascular risk and measured lipid outcomes.

Latar belakang: Audit peresepan memberikan dasar untuk mengevaluasi ketepatan pengobatan antihiperlipidemia dalam praktik klinis. Tujuan: Mendeskripsikan pola peresepan dan menilai ketepatannya berdasarkan dokumentasi di RSU Imelda Pekerja Indonesia, Medan. Metode: Penelitian deskriptif ini menelaah rekam medis periode Maret 2025–Februari 2026 secara retrospektif. Data dikumpulkan pada Juni 2026, dengan 51 pasien dipilih melalui purposive sampling. Ketepatan pasien, indikasi, obat, dosis, dan cara pemberian dinilai dengan mengacu pada panduan Perkumpulan Endokrinologi Indonesia (PERKENI) tahun 2021. Data disajikan sebagai frekuensi, persentase, dan interval kepercayaan (IK) eksak 95%. Hasil: Pasien perempuan berjumlah 32 orang (62,75%); kelompok usia terbanyak adalah 56–65 tahun (16; 31,37%). Monoterapi simvastatin 20 mg, atorvastatin 20 mg, dan fenofibrat 300 mg masing-masing tercatat pada 26 (50,98%), 19 (37,25%), dan empat (7,84%) pasien. Dua pasien (3,92%) menerima simvastatin 20 mg bersama fenofibrat 100 mg. Monoterapi statin mencakup 88,24% pasien (IK 95%, 76,13–95,56%). Seluruh 51 rekam medis diklasifikasikan tepat pada setiap kriteria (100%; IK 95%, 93,02–100,00%). Kesimpulan: Monoterapi statin mendominasi, dan tidak ditemukan ketidaktepatan yang terdokumentasi dalam lima kriteria yang dinilai. Temuan ini menggambarkan klasifikasi ketepatan peresepan, bukan keamanan terapi secara menyeluruh atau pencapaian target lipid. Evaluasi selanjutnya perlu menghubungkan keputusan peresepan dengan risiko kardiovaskular individual dan luaran lipid yang terukur.